Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer

Simple item page
dc.contributor.authorQiang, Lien_US
dc.contributor.authorMeng, Jiangen_US
dc.contributor.authorXiao, Hanen_US
dc.contributor.authorYang, Zheen_US
dc.contributor.authorShu, Weibinen_US
dc.contributor.authorDing, Xiaoen_US
dc.date.accessioned2020-11-18T10:08:17Z
dc.date.available2020-11-18T10:08:17Z
dc.date.issued2020-05
dc.description.abstractAims: The aim of this study is to investigate patients with unresectable Stage III non-small-cell lung cancer (NSCLC) receiving radiotherapy with induction and concurrent pemetrexed or docetaxel plus cisplatin (PP/DP) chemotherapy and to identify the subgroup most likely to benefit from induction chemotherapy (IC). Subjects and Methods: Patients with unresectable measurable Stage III NSCLC received two cycles of PP/DP IC followed by concurrent chemoradiotherapy at a dose of 60–66 Gy. Statistical Analysis Used: Cox regression analysis was performed to evaluate the prognostic factors for survival; logistic regression analysis was used to evaluate the predictors for response to IC, and the receiver operating characteristic curves were used to evaluate the independent factors predicting response. Results: Eighty patients were included; the median survival time (MST) was 22.1 months. Partial response (PR) to IC was an independent prognostic factor for overall survival. For patients in the PR and stable disease groups, the MST was 36.7 and 19.5 months, respectively. The independent predictors of PR to IC included classification as stage N3 cancer, baseline carcinoembryonic antigen (CEA) levels >10 ng/ml, and cytokeratin fragment 19 (CYFRA21-1) levels >6 ng/ml. With each additional independent predictor, the likelihood of having have PR to IC increased. Conclusions: Radiotherapy with induction and concurrent PP/DP chemotherapy is feasible for patients with unresectable Stage III NSCLC. IC may improve the survival of IC responders, as predicted by elevated CEA and CYFRA21-1 levels and classification as stage N3 cancer. Additional randomized trials on IC may consider these predictors to tailor individualized treatmentsen_US
dc.identifier.affiliationsCancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Chinaen_US
dc.identifier.affiliationsDepartment of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Chinaen_US
dc.identifier.affiliationsDepartment of Experimental, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Chinaen_US
dc.identifier.affiliationsCancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Chinaen_US
dc.identifier.affiliationsCancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Chinaen_US
dc.identifier.affiliationsCancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Chinaen_US
dc.identifier.citationQiang Li, Meng Jiang, Xiao Han, Yang Zhe, Shu Weibin, Ding Xiao. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer. Journal of Cancer Research and Therapeutics. 2020 May; 16(2): 222-229en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213804
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber2en_US
dc.relation.volume16en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_710_19en_US
dc.subjectCarcinoembryonic antigenen_US
dc.subjectcytokeratin fragment 19en_US
dc.subjectinduction chemotherapyen_US
dc.subjectpartial responseen_US
dc.subjectStage III non‑small‑cell lung canceren_US
dc.titleInduction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2020v16n2p222.pdf
Size:
796.35 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics